ESMO 2025 - Complete program listing (23)

Daily recaps and interviews from the ESMO 2025

Drs. Jamil Asselah, Rami Younan, and Kim Ma review major Day 1 updates from ESMO 2025 in early breast cancer—monarchE overall survival, 5-year NATALEE, and POSITIVE trial results—while previewing upcoming data in neoadjuvant, post-neoadjuvant, and metastatic settings to be discussed in the days ahead.

Drs. Kim Ma and Nathalie LeVasseur review and discuss adjuvant CDK4/6 inhibitor data presented on Day 1 of ESMO 2025, highlighting key updates from monarchE and NATALEE trials and how these findings may influence patient care in early breast cancer.

Dr. Sara Hurvitz reviews findings from VIKTORIA-1, a phase 3 international open-label randomized trial, highlighting early promising trends that may influence treatment strategies and improve patient outcomes in breast cancer care.

Dr. Karen Gelmon shares her reflections from Day 2 at ESMO 2025, highlighting the POSITIVE trial and its impact on pregnancy outcomes for women wishing to conceive, along with her insights and guidance for both patients and clinicians.

Drs. Asselah, Younan, and Ma share Day 2 highlights from ESMO 2025, noting encouraging results across breast cancer studies, with special mentions to DESTINY-Breast11, DESTINY-Breast05, ASCENT-03, and TROPION-Breast02 — and more exciting updates to come tomorrow.

Dr. Sara Soldera discusses the monarchE study results presented at ESMO 2025, highlighting the overall survival benefit in the adjuvant setting, how these findings reinforce current practice, and what they mean for patients with early breast cancer.

Dr. Kevin Kalinsky shares his perspective on the most significant breast cancer data from ESMO 2025, including updates from NATALEE, monarchE, DESTINY-Breast05 & 11, ASCENT-03, and TROPION-Breast02—highlighting key findings shaping treatment practice.

Dr. Mita Manna shares her review of the latest breast cancer data from ESMO 2025, covering all three major subtypes. As Chair of the REAL Alliance, she also announces upcoming consensus recommendations and Canadian practice guidance to be published soon.

Dr. Christos Sotiriou shares key insights from his ESMO 2025 presentation on exceptional responders in metastatic cancer, exploring molecular and clinical factors that help identify patients who achieve extraordinary outcomes with targeted therapies.

Prof. Rebecca Dent presents the much-anticipated primary results from the randomized phase III TROPION-Breast02 trial at ESMO 2025, sharing key outcomes that could redefine treatment strategies in advanced breast cancer.

Dr. Kim Ma and Dr. Jean-Pierre Ayoub wrap up Day 3 of ESMO 2025 with key insights from the evERA Breast Cancer study—covering patient benefits, safety, and access—before discussing the VIKTORIA-1 results from ESMO, where Dr. Ayoub shares insights as an investigator from CHUM.

Dr. Kim Ma shares her main takeaways from ESMO 2025, reflecting on three days of impactful breast cancer data—from adjuvant CDK4/6 trials monarchE and NATALEE, to metastatic insights from TROPION-Breast02, ASCENT-03, and the promising evERA Breast Cancer trial shaping future care.

Dr. Hope Rugo reviews practice-changing updates from ESMO 2025 across HER2-positive, triple-negative, and hormone receptor–positive breast cancer, highlighting early-stage results from monarchE and NATALEE, and key findings from the phase 3 evERA Breast Cancer study in the metastatic setting.

Dr. Sara Tolaney reviews practice-changing data from ESMO 2025 in early-stage HER2-positive breast cancer, highlighting major shifts in clinical practice with findings from DESTINY-Breast11 in the neoadjuvant setting and DESTINY-Breast05 in the post-neoadjuvant setting.

Dr. Jean-Pierre Ayoub discusses studies from ESMO 2025 that could soon impact breast oncology practice, including TROPION-Breast02 and ASCENT-03 for metastatic TNBC, along with HER2-positive updates from DESTINY-Breast11 and DESTINY-Breast05 with T-DXd therapy.

Dr. Charles Geyer highlights his presentation from ESMO 2025’s first Presidential Symposium, featuring the interim analysis of the DESTINY-Breast05 trial—a follow-up to the KATHERINE study—and walks us through the key data and its clinical implications.

Dr. Neil Iyengar discusses prevention-focused work from ESMO 2025, highlighting insights from the ESMO Task Force meta-analysis of 91 drug prevention trials, examining which strategies show benefit and where future efforts should focus.

Dr. Neil Iyengar discusses the ESMO 2025 session on survivorship in young-onset cancers, a growing global concern often linked to obesity-driven diseases, and highlights how lifestyle, exercise, and digital tools can improve prevention and long-term outcomes.

Dr. Christine Brezden-Masley shares her insights from ESMO 2025, reviewing the ASCENT-03 trial in metastatic triple-negative breast cancer and reflecting on how emerging data continues to inform treatment decisions and patient care.

Dr. Claudio Vernieri shares key insights from his ESMO 2025 poster exploring the real-world effectiveness of first-line endocrine therapy combined with CDK4/6 inhibitors in HR+/HER2- advanced breast cancer, focusing on treatment outcomes and clinical implications.

Dr. Paolo Tarantino dives into the latest ADC-driven shifts from ESMO 2025 across breast cancer subtypes—reviewing TROPION-Breast02, ASCENT-03, DESTINY-Breast11, and DESTINY-Breast05—and shares what should be the overall learning from this year’s ESMO.

Dr. Katarzyna Jerzak shares key take-aways from ESMO 2025 across breast cancer subtypes. She reviews HR+/HER2- early-stage data from monarchE and NATALEE, reflecting on how these findings could influence patient care soon.

Dr. Hiba Moukadem, medical oncologist and breast cancer specialist at the American University of Beirut Medical Center, reviews results from two key Presidential Session abstracts at ESMO 2025 — DESTINY-Breast05 and DESTINY-Breast11 — and their clinical implications.